Mainor Candace B, Duffy Alison P, Atkins Kristin L, Kimball Amy S, Baer Maria R
Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, USA.
J Oncol Pharm Pract. 2016 Apr;22(2):374-7. doi: 10.1177/1078155214568582. Epub 2015 Jan 23.
BCR-ABL inhibitors administered in conjunction with chemotherapy have significantly improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia but, for patients diagnosed during pregnancy, data on risks to the fetus are limited. We report a woman treated with chemotherapy and imatinib mesylate who delivered a healthy baby at 30 weeks, and we discuss available data.
与化疗联合使用的BCR-ABL抑制剂显著改善了费城染色体阳性急性淋巴细胞白血病的治疗效果，但对于孕期确诊的患者，关于胎儿风险的数据有限。我们报告了一名接受化疗和甲磺酸伊马替尼治疗的女性，她在30周时产下一名健康婴儿，并讨论了现有数据。
